Ablevia's proprietary platform technology enables development of infusible therapeutics that target harmful antibodies in autoimmune conditions, transplant rejection, or anti-drug antibodies that neutralize biotherapeutics.
We develop antibody depleting compounds that are readily adapted to target selectively undesired and disease-causing antibodies in rare diseases and conditions with unmet clinical needs.
Founded in 2018 at the Vienna Biocenter Campus, Ablevia focuses on preclinical research and development. We are currently reaching out for cooperation programs with strong partners in need of addressing undesired antibodies in preclinical and clinical development.
supported by BMWFW / aws & FFG